Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting
Betsy Goodfellow | June 5, 2023 | News story | Research and Development | Allogene, LBCL, Oncology, lymphoma, oncology
Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). The data was announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US. The data is also expected to be shared at a poster session at the European Hematology Associate (EHA) Hybrid Congress on 9 June 2023.
This updated analysis of ALPHA/ALPHA2 considered data from 12 CAR T-naïve patients with r/r LBCL who were treated with a single dose of ALLO-501/501A alongside other treatments. The median time from enrollment to treatment was three days and all of the patients were followed through a six-month period.
Following the six months, seven of the patients (58%) saw a complete response (CR) and five (42%) maintained a CR throughout month 6; of those five, four (80%) remained in CR. The median duration of response was 23.1 months, with three patients remaining in remission for more than 24 months, the longest being 31 months.
Zachary Roberts, MD PhD, executive vice president of research and development and chief medical officer at Allogene, commented: “We are excited to be the first to demonstrate the potential of allogeneic CD19 CAR T to induce durable complete remissions at a rate similar to approved autologous CD19 CAR T therapies. Our phase 2 regimen also had a safety profile, including immune recovery, in line with approved options. We believe our AlloCAR T product candidates have the potential to break down widespread access barriers to CAR T, and ultimately establish a new paradigm in cell therapy. This data underlines the excitement we and investigators have for our ongoing potentially pivotal phase 2 ALPHA2 trial.”
Betsy Goodfellow
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
